image

Investors

Corporate Profile

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Archived Events
32nd Annual Oppenheimer Healthcare Conference
March 15, 2022 at 4:00 PM EDT
View Webcast
11th Annual SVB Leerink Global Healthcare Conference
February 17, 2022 at 3:40 PM EST
View Webcast
Discussion of Initial NX-2127 Phase 1a PK/ PD Data
October 27, 2021 at 8:30 AM EDT
View Webcast
Corporate Presentations
Scientific Presentation
Print Page
Email Alerts
RSS Feeds
Contact IR